Evaluation of Natural Peptides to Prevent and Reduce the Novel SARS-CoV-2 Infection

Table 1

Angiotensin-converting enzyme 2 (ACE2) docking analysis.

Drug/peptide	E bondglobal (kcal/mol)	E bondkey residues (kcal/mol)			Drug/peptide	E bondglobal (kcal/mol)	E bondkey residues (kcal/mol)
Ritonavir (347980)	−7,98	>−2			IGV	−5,05	−2,557
	−5,86	−2,274		−2,080		−4,7	>−2
	−5,79	−2,279	−2,055	−2,313	IVG	−5,25	−3,559
Lopinavir (83706)	−5,88	−2,557				−4,88	−2,106
	−5,3	−2,903			VGVL	−5,14	>−2
	−4,85	>−2				−4,93	−4,000
Emtricitabine (54859)	−4,94	−5,184				−4,28	−5,587
	−4,83	−4,453			VIKP	−5,18	−2,049
Hydroxychloroquine (3526)	−5,06	>−2				−4,69	>−2
	−4,71	>−2			LSDRFS	−4,66	−2,543
	−4,46	−3,965				−5,93	−4,115		−8,610
Chloroquine (2618)	−4,8	>−1				−5,69	−5,649	−2,366	−2,557
	−4,39	>−2				−5,51	−2,351
	−4,18	>−2				−4,69	−11,390		−2,191
GGV	−5,78	−4,866			SDRFSY	−7,56	−5,494
	−4,76	−2,557				−6,32	−2,759	−2,352	−4,389
	−4,32	−3,576				−6,05	−6,452